As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime ...

Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...

A Cleveland Clinic-led research collaboration between Timothy Chan, MD, PhD, Chair of Cleveland Clinic's Global Center for ...

Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations early in treatment were linked to greater probability of sustained remission.

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, a new study found.

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

A health communications partnership has been launched today by UK strategic comms agency Lexington Communications and US ...

Vice presidential candidates Tim Walz and JD Vance will face off today in the only vice presidential debate in an election where health care issues, including abortion and affordability, have taken ...